Evidence map›Paper›PMID 28560695›Full record

ArticlePharmaceutical research2017

High-Tech Drugs in Creaky Formulations.

Maikel Herbrink, Bastiaan Nuijen, Jan H M Schellens, Jos H Beijnen

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Therapeutic drug monitoring of oral targeted antineoplastic drugs.European journal of clinical pharmacology · 2021
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Maikel HerbrinkThe Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. m.herbrink@nki.nl.
Bastiaan NuijenThe Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Jan H M SchellensThe Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Jos H BeijnenThe Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
The Netherlands Cancer Institute · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent literature reviews and registration documents covering novel Signal Transduction Inhibitors in the treatment of cancer paint a picture of inefficiency and variability, where formulation improvements could be valuable. In this article, we discuss apparent drug design flaws as we impose the current standard formulation practice.

Indexed as

Drug DesignAntineoplastic AgentsBiopharmaceuticsDrug CompoundingHumansMolecular Targeted TherapyNeoplasmsSignal TransductionSolubilityAntineoplastic Agentsanticancer drugsbiopharmaceuticsformulationpharmaceutics

Identifiers

PMID28560695
OpenAlexW2617754438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.